Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Argenx SE    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 07/13 07:25:49 am
224.2 EUR   +0.54%
06/24ARGENX : Announces Positive Topline Phase 3 ADAPT Trial Results
PU
06/24ARGENX : Positive Topline Phase 3 ADAPT Trial Results
PU
06/24ARGENX : Securities Note
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
217.4(c) 217.8(c) 223.8(c) 223(c) 224 Last
81 109 82 438 80 497 63 214 17 123 Volume
+3.23% +0.18% +2.75% -0.36% +0.45% Change
More quotes
Financials
Sales 2020 80,6 M 91,2 M 91,2 M
Net income 2020 -400 M -453 M -453 M
Net cash position 2020 967 M 1 094 M 1 094 M
P/E ratio 2020 -22,7x
Yield 2020 -
Sales 2021 122 M 138 M 138 M
Net income 2021 -424 M -480 M -480 M
Net cash position 2021 891 M 1 008 M 1 008 M
P/E ratio 2021 -19,7x
Yield 2021 -
Capitalization 10 721 M 12 129 M 12 133 M
EV / Sales 2020 121x
EV / Sales 2021 80,5x
Nbr of Employees 186
Free-Float 99,4%
More Financials
Company
argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical... 
More about the company
Surperformance© ratings of argenx SE
Trading Rating : Investor Rating :
More Ratings
Latest news on ARGENX SE
06/24ARGENX : Announces Positive Topline Phase 3 ADAPT Trial Results
PU
06/24ARGENX : Positive Topline Phase 3 ADAPT Trial Results
PU
06/24ARGENX : Securities Note
PU
06/01argenx announces closing of global offering
GL
06/01ARGENX SE : Admission of new securities
CO
05/29argenx announces full exercise of underwriters' option to purchase additional..
GL
05/28argenx raises $750 million in gross proceeds in a global offering
GL
05/26argenx announces launch of proposed global offering
GL
05/26argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgarti..
GL
05/14argenx reports first quarter 2020 financial results and provides business upd..
GL
05/14ARGENX SE : Slide show Q1 results
CO
05/13ARGENX : announces results of Annual General Meeting of Shareholders
AQ
05/11ARGENX : to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020..
AQ
05/11ARGENX SE : quaterly earnings release
05/08ARGENX : to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020..
PU
More news
News in other languages on ARGENX SE
06/24ARGENX : Announces Positive Topline Phase 3 ADAPT Trial Results
06/24ARGENX : Positive Topline Phase 3 ADAPT Trial Results
06/24ARGENX : Securities Note
06/01argenx announces closing of global offering
05/29argenx announces full exercise of underwriters' option to purchase additional..
More news
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 216,80 €
Last Close Price 223,00 €
Spread / Highest target 30,0%
Spread / Average Target -2,78%
Spread / Lowest Target -39,5%
EPS Revisions
Managers
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGENX SE55.29%12 129
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955